November $10B+ M&A Deals Set Q4 Up To Outpace Prior Quarter
Summarize this article with:
Markit3.51K FollowersFollow5ShareSavePlay(5min)CommentsSummaryNovember's announced M&A deals of more than $10 billion in transaction value brought the fourth quarter's worldwide tally to 11 deals.Abbott Laboratories plans to acquire Exact Sciences Corp. in a deal with a transaction value of $22.54 billion.In a specialty chemicals deal announced Nov. 18 with a transaction value of $12.05 billion, Nobel NV plans to acquire Axalta Coating Systems. narvo vexar/iStock via Getty Images November's announced M&A deals of more than $10 billion in transaction value brought the fourth quarter's worldwide tally to 11 deals. Through the first two months of the period, the fourth quarter deal count alreadyThis article was written byMarkit3.51K FollowersFollowIHS Markit (Nasdaq: INFO) is a world leader in critical information, analytics and solutions for the major industries and markets that drive economies worldwide. The company delivers next-generation information, analytics and solutions to customers in business, finance and government, improving their operational efficiency and providing deep insights that lead to well-informed, confident decisions. IHS Markit has more than 50,000 key business and government customers, including 80 percent of the Fortune Global 500 and the world’s leading financial institutions. Headquartered in London, IHS Markit is committed to sustainable, profitable growth.Quick InsightsHow does the KMB-KVUE merger address recent Tylenol-related headlines?KMB and KVUE leadership emphasized rigorous review and ongoing confidence in Tylenol's safety, stating the deal was not influenced by recent headlines or regulatory commentary.What is the strategic rationale for ABT's acquisition of EXAS at $105/share?ABT aims to strengthen its diagnostics leadership and expand into high-growth cancer screening, acquiring EXAS for $105 per share in an all-cash transaction.What are the financial and ownership terms of the Akzo Nobel–Axalta merger?The all-stock merger of equals provides no premium; Axalta shareholders receive AkzoNobel shares, owning 45% of the combined $25B enterprise-value company.Recommended For You